After signing up, you'll start to receive regular news updates from us.
Cerep and Servier Enter Collaboration Agreements
Complete the form below to unlock access to ALL audio articles.
Cerep and Servier have announced the signing of three collaboration agreements. The first two research agreements provide that Cerep will apply its know-how and technologies in high-throughput screening and medicinal chemistry to identify molecules active on targets selected by Servier.
In the first program, Cerep will screen its proprietary chemical compound library and will perform lead optimization of hits identified through the screening.
The second program consists of a large screening of Cerep’s library to identify hits to be transferred to Servier for further optimization.
According to the terms of the third agreement, Cerep will apply BioPrint® tools to characterize drug candi-dates selected by Servier in order to identify those with the best chances of success in clinical development.
Cerep will be paid on the basis of the number of analysis performed for its partner.
Thierry Jean, CEO of Cerep commented, "We are delighted to extend and strengthen our partnership with Servier, an internationally recognized pharmaceutical company."
"Servier has been our first customer, at the time of Cerep’s creation in 1990, and we have since been well positioned to bene.t from its scientific expertise."
"We are particularly proud to have been selected for these new programs. The extension of our relationship with Servier to chemistry and the use of BioPrint® illustrate the progress of Cerep all along these past 16 years."
Laurent Perret, President Research and Development, Servier, commented, "These agreements are part of the historical partnership between the two companies, initiated more than 15 years ago, and illustrate the supportive commitment of Servier for biotechnology companies in France, such as Cerep."
Emmanuel Canet, Vice-President Research and Development, Servier, commented, "This alliance illustrates the quality of the relationship that we always maintained with Cerep."
"We are very happy to link the R&D efforts of both companies and to have access to BioPrint® for the selection and optimization of our future medicines."
